GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Debt-to-EBITDA
中文

Samsung BioLogics Co (XKRX:207940) Debt-to-EBITDA : 0.92 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Samsung BioLogics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩1,531,936 Mil. Samsung BioLogics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩377,397 Mil. Samsung BioLogics Co's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩2,068,509 Mil. Samsung BioLogics Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.92.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Samsung BioLogics Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:207940' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -13.52   Med: 1.44   Max: 2.13
Current: 1.13

During the past 10 years, the highest Debt-to-EBITDA Ratio of Samsung BioLogics Co was 2.13. The lowest was -13.52. And the median was 1.44.

XKRX:207940's Debt-to-EBITDA is ranked better than
52.33% of 279 companies
in the Biotechnology industry
Industry Median: 1.39 vs XKRX:207940: 1.13

Samsung BioLogics Co Debt-to-EBITDA Historical Data

The historical data trend for Samsung BioLogics Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co Debt-to-EBITDA Chart

Samsung BioLogics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.08 1.84 1.75 1.82 1.13

Samsung BioLogics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 1.92 1.56 1.15 0.92

Competitive Comparison of Samsung BioLogics Co's Debt-to-EBITDA

For the Biotechnology subindustry, Samsung BioLogics Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samsung BioLogics Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's Debt-to-EBITDA falls into.



Samsung BioLogics Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Samsung BioLogics Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1531935.793 + 377396.784) / 1691365.327
=1.13

Samsung BioLogics Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1531935.793 + 377396.784) / 2068508.556
=0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Samsung BioLogics Co  (XKRX:207940) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Samsung BioLogics Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Samsung BioLogics Co (XKRX:207940) Business Description

Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu,, Incheon, KOR
Samsung BioLogics Co Ltd engaged in development and manufacturing of bio-healthcare products.The Company works namely in Process Development, cGMP Manufacturing, Aseptic Fill and Finish.

Samsung BioLogics Co (XKRX:207940) Headlines

No Headlines